HK1009331A1 - Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders - Google Patents
Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders Download PDFInfo
- Publication number
- HK1009331A1 HK1009331A1 HK98110056A HK98110056A HK1009331A1 HK 1009331 A1 HK1009331 A1 HK 1009331A1 HK 98110056 A HK98110056 A HK 98110056A HK 98110056 A HK98110056 A HK 98110056A HK 1009331 A1 HK1009331 A1 HK 1009331A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- phenyl
- pyridineethanamine
- pharmaceutically acceptable
- treatment
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929207339A GB9207339D0 (en) | 1992-04-03 | 1992-04-03 | Pharmaceutical compound |
| GB9207339 | 1992-04-03 | ||
| GB929208290A GB9208290D0 (en) | 1992-04-15 | 1992-04-15 | Pharmaceutical compound having neuroprotective properties |
| GB9208290 | 1992-04-15 | ||
| PCT/GB1993/000689 WO1993020052A1 (en) | 1992-04-03 | 1993-04-01 | Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1009331B HK1009331B (en) | 1999-05-28 |
| HK1009331A1 true HK1009331A1 (en) | 1999-05-28 |
Family
ID=26300643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK98110056A HK1009331A1 (en) | 1992-04-03 | 1993-04-01 | Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0633879B1 (enExample) |
| JP (2) | JP3120810B2 (enExample) |
| KR (1) | KR100259567B1 (enExample) |
| CN (1) | CN1044367C (enExample) |
| AT (1) | ATE163925T1 (enExample) |
| AU (2) | AU3897693A (enExample) |
| CA (1) | CA2133427C (enExample) |
| CZ (1) | CZ288519B6 (enExample) |
| DE (1) | DE69317411T2 (enExample) |
| DK (1) | DK0633879T3 (enExample) |
| DZ (1) | DZ1677A1 (enExample) |
| ES (1) | ES2115055T3 (enExample) |
| FI (1) | FI105025B (enExample) |
| HK (1) | HK1009331A1 (enExample) |
| HU (1) | HU211529A9 (enExample) |
| IL (1) | IL105276A (enExample) |
| MA (1) | MA22866A1 (enExample) |
| MX (1) | MX9301935A (enExample) |
| MY (1) | MY110149A (enExample) |
| NO (1) | NO302170B1 (enExample) |
| NZ (1) | NZ251384A (enExample) |
| PL (1) | PL180014B1 (enExample) |
| RU (1) | RU2128650C1 (enExample) |
| SG (1) | SG47948A1 (enExample) |
| SK (1) | SK281258B6 (enExample) |
| TW (1) | TW282455B (enExample) |
| UA (1) | UA29437C2 (enExample) |
| WO (1) | WO1993020052A1 (enExample) |
| ZA (1) | ZA932415B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320273D0 (en) | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| ATE135206T1 (de) * | 1988-08-12 | 1996-03-15 | Astra Ab | Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung |
| ZA942140B (en) * | 1993-04-01 | 1994-10-03 | Fisons Corp | Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901237D0 (sv) * | 1999-04-06 | 1999-04-06 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| US6380224B1 (en) * | 1999-07-28 | 2002-04-30 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| WO2007017652A2 (en) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Arylakylamines for the treatment of cancer |
| PE20120249A1 (es) | 2008-12-24 | 2012-04-19 | Astrazeneca Ab | Compuestos etanaminicos |
| WO2013088135A1 (en) | 2011-12-14 | 2013-06-20 | Astrazeneca Ab | Gabr-a2 diagnostic |
| DK3066091T3 (da) | 2013-11-05 | 2019-07-15 | Astrazeneca Ab | Nmda-antagonist-prodrugs |
| PH12022553502A1 (en) * | 2020-06-23 | 2024-04-22 | Biohaven Therapeutics Ltd | Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA889252B (en) * | 1987-12-11 | 1990-08-29 | Syntex Lab | Neuroprotective compounds |
| ATE135206T1 (de) * | 1988-08-12 | 1996-03-15 | Astra Ab | Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung |
-
1993
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active Expired - Lifetime
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 HK HK98110056A patent/HK1009331A1/en not_active IP Right Cessation
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 EP EP93907975A patent/EP0633879B1/en not_active Expired - Lifetime
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/en not_active Ceased
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 CA CA002133427A patent/CA2133427C/en not_active Expired - Lifetime
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
-
1994
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
-
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
-
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
-
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0633879B1 (en) | Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders | |
| HK1009331B (en) | Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders | |
| EP0691957B1 (en) | (s)-alpha-phenyl-2-pyridineethanamine (s)-malate and its use as a medicament | |
| JPH06293761A (ja) | スピロ橋かけ型および非橋かけ型複素環式化合物 | |
| US5455259A (en) | Compounds for the treatment of neurodegenerative disorders | |
| DE69230498T2 (de) | 2-Pyrazinylethylamin-Derivate und ihre Verwendung als Arzneimittel. | |
| EP0691958B1 (en) | (s)-alpha-phenyl-2-pyridineethanamine benzoate and its use as a medicament | |
| CA2028645A1 (en) | Use of arylalkylamides in the treatment of neurodegenerative diseases | |
| TW390875B (en) | (S) -<alpha>-phenyl-2-pyridineethanamine (S)-malate useful in therary, its perparing process and pharmaceutical composition comprising the same | |
| EP1596856A2 (de) | Arzneimittel enthaltend substituierte 2-aryl-aminoessigs ure -verbindungen und/oder substituierte 2-heteroaryl-aminoessigsäure-verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PF | Patent in force | ||
| PE | Patent expired |
Effective date: 20130331 |